PCM
DFTX

Pinz Capital Management’s Definium Therapeutics DFTX Stock Holding History

Pinz Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-413
Closed -$21K – 302
2021
Q2 		$21K Buy
+413
New +$21.7K 0.01% 346

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Pinz Capital Management's DFTX Position: Q3 2021 in Review

Pinz Capital Management sold out of Definium Therapeutics (DFTX) in Q3 2021, closing a stake of 413 shares — an estimated $21K sold.

Pinz Capital Management first reported a position in DFTX in Q2 2021 and held it in 1 quarter. The position peaked at $21K in Q2 2021. 174 funds tracked by Wall St. Rank hold DFTX as of Q3 2021.

  • Pinz Capital Management reported no remaining Definium Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 413 Definium Therapeutics shares in Q3 2021, an estimated $21K.
  • Pinz Capital Management first reported a position in Definium Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Definium Therapeutics position peaked at $21K in Q2 2021.
  • 174 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.